STROMAL INFLUENCES ON BREAST CANCER PROGRESSION
间质对乳腺癌进展的影响
基本信息
- 批准号:2633893
- 负责人:
- 金额:$ 11.57万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1995
- 资助国家:美国
- 起止时间:1995-01-01 至 1999-12-31
- 项目状态:已结题
- 来源:
- 关键词:MCF7 cell RNase protection assay angiogenesis angiogenesis factor biomarker breast neoplasms fibroblast growth factor genetic transcription immunocytochemistry in situ hybridization microcirculation neoplasm /cancer blood supply neoplasm /cancer pharmacology neoplastic process pentosan polymerase chain reaction receptor expression stainings stromal cells tamoxifen transfection vascular endothelium
项目摘要
Transfection of MCF-7 breast carcinoma cells with fibroblast growth
factor 4 (FGF-4), an angiogenic growth factor, produces a dramatic change
in tumor phenotype when the cells are injected into the mammary fat pads
of ovariectomized nude mice. While the parental cells are estrogen-
dependent for tumor growth, poorly invasive, and rarely metastatic, the
transfectants produce large, progressively growing tumors which are
invasive, frequently metastatic and growth-stimulated by tamoxifen, an
estrogen antagonist. This in vivo behavior of the transfectants is in
contrast to their in vitro behavior, which is not substantially different
from the parental MCF-7 cells (specifically, the transfectants are not
growth-stimulated by tamoxifen in vitro). Thus, it would seem likely that
at least some portion of the change in in vivo phenotype is due to an
interaction between the transfected gene product and stromal components
of the tumor. Since the transfected gene product is a known angiogenic
growth factor, it seems likely that increased angiogenesis in tumors
produced by-the transfected cells is at least partially responsible for
the change in in vivo phenotype produced by the transfection. A number
of FGF receptor (FGFR) genes have been identified which may each encode
multiple receptors via alternative mRNA splicing. Evidence is emerging
which attributes specific responses or affinity for specific FGF ligands
to specific FGFR isoforms. Specific FGFRs in tumors produced by
transfected cells may respond to the FGF-4 ligand and/or be up- or down-
regulated. Evidence is also accumulating that endothelial cells from
specific tissues differ, and that endothelial cells from tumors are
different from those in normal tissues. Cultured endothelial cells are
quite plastic in their gene expression and behavior depending on their
passage and growth conditions. Therefore, attempts to study tumor
angiogenesis in vitro must use appropriate endothelial cells under
appropriate conditions. This project seeks to relate changes in the
process of angiogenesis in tumors produced by parental and FGF-4
transfected MCF-7 cells to the change in in vivo behavior. We will
relate microvessel density and total vascularity to tumor size in tumors
produced by parental and transfected cells. We will describe the process
of angiogenesis in tumors produced by parental and transfected cells by
techniques which identify proliferating or immature endothelial cells in
tumor sections obtained at very early and later time points after
injection of tumor cells. The project will also seek to characterize
specific in situ FGFR expression by endothelial and other cells contained
within the tumor. We will isolate endothelial cells from tumors produced
by parental or FGF-4 transfected MCF-7 cells as well as endothelial cells
from normal mammary fat pads. Growth assays in which quiescent cells are
stimulated to invade a 3-dimensional matrix will be done utilizing very
early passage tumor-derived and normal endothelial cells to identify
differences in behavior between the three types of endothelial cells.
Tumor-derived and mammary fat pad endothelial cells will be subjected to
differential display PCR in a search for genes which are preferentially
expressed in tumors produced by FGF-4 transfected MCF-7 cells.
Transcription of such genes might be an important downstream event of
FGFR stimulation and the protein products of such genes might be
important in determining the phenotype of the tumor.
转染成纤维细胞生长的MCF-7乳腺癌细胞
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SANDRA W MCLESKEY其他文献
SANDRA W MCLESKEY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SANDRA W MCLESKEY', 18)}}的其他基金
INFLUENCE OF GROWTH FACTORS ON BREAST CANCER PROGRESSION
生长因子对乳腺癌进展的影响
- 批准号:
3034680 - 财政年份:1992
- 资助金额:
$ 11.57万 - 项目类别:
INFLUENCE OF GROWTH FACTORS ON BREAST CANCER PROGRESSION
生长因子对乳腺癌进展的影响
- 批准号:
2085089 - 财政年份:1992
- 资助金额:
$ 11.57万 - 项目类别:
相似海外基金
NOVEL RNASE PROTECTION ASSAY FOR CYTOKINE MRNAS
细胞因子 MRNAS 的新型 RNA 酶保护测定
- 批准号:
6317727 - 财政年份:2000
- 资助金额:
$ 11.57万 - 项目类别: